Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A.

Oncotarget. 2017 May 23;8(34):56684-56697. doi: 10.18632/oncotarget.18079. eCollection 2017 Aug 22.

2.

Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.

Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ.

Oncotarget. 2017 Feb 7;8(6):9617-9633. doi: 10.18632/oncotarget.14168.

3.

Recruitment of Tiam1 to Semaphorin 4D Activates Rac and Enhances Proliferation, Invasion, and Metastasis in Oral Squamous Cell Carcinoma.

Zhou H, Kann MG, Mallory EK, Yang YH, Bugshan A, Binmadi NO, Basile JR.

Neoplasia. 2017 Feb;19(2):65-74. doi: 10.1016/j.neo.2016.12.004. Epub 2016 Dec 27.

4.

Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.

Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh WK, Zhu J.

Oncotarget. 2016 Oct 18;7(42):68688-68707. doi: 10.18632/oncotarget.11925.

5.

The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer.

Ding X, Qiu L, Zhang L, Xi J, Li D, Huang X, Zhao Y, Wang X, Sun Q.

Onco Targets Ther. 2016 Mar 8;9:1189-204. doi: 10.2147/OTT.S98906. eCollection 2016.

6.

Semaphorin 4D Promotes Skeletal Metastasis in Breast Cancer.

Yang YH, Buhamrah A, Schneider A, Lin YL, Zhou H, Bugshan A, Basile JR.

PLoS One. 2016 Feb 24;11(2):e0150151. doi: 10.1371/journal.pone.0150151. eCollection 2016.

7.

ARF-GEF cytohesin-2/ARNO regulates R-Ras and α5-integrin recycling through an EHD1-positive compartment.

Salem JC, Reviriego-Mendoza MM, Santy LC.

Mol Biol Cell. 2015 Nov 15;26(23):4265-79. doi: 10.1091/mbc.E15-05-0278. Epub 2015 Sep 16.

8.

Loss of plexin-B3 in hepatocellular carcinoma.

Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen Z, He Q, Feng D.

Exp Ther Med. 2015 Apr;9(4):1247-1252. Epub 2015 Jan 30.

9.

A cytosolic juxtamembrane interface modulates plexin A3 oligomerization and signal transduction.

Barton R, Palacio D, Iovine MK, Berger BW.

PLoS One. 2015 Jan 7;10(1):e0116368. doi: 10.1371/journal.pone.0116368. eCollection 2015.

10.

The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22.

11.

VEGF targets the tumour cell.

Goel HL, Mercurio AM.

Nat Rev Cancer. 2013 Dec;13(12):871-82. doi: 10.1038/nrc3627. Review.

12.

Function of mutant and wild-type plexinb1 in prostate cancer cells.

Damola A, Legendre A, Ball S, Masters JR, Williamson M.

Prostate. 2013 Sep;73(12):1326-35. doi: 10.1002/pros.22678. Epub 2013 Jun 15.

13.

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE.

Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17.

14.

The role of semaphorins and their receptors in gliomas.

Law JW, Lee AY.

J Signal Transduct. 2012;2012:902854. doi: 10.1155/2012/902854. Epub 2012 Sep 23.

15.

Neuropilins: expression and roles in the epithelium.

Wild JR, Staton CA, Chapple K, Corfe BM.

Int J Exp Pathol. 2012 Apr;93(2):81-103. doi: 10.1111/j.1365-2613.2012.00810.x. Review.

16.

Effect of cancer-associated mutations in the PlexinB1 gene.

Zhou C, Wong OG, Masters JR, Williamson M.

Mol Cancer. 2012 Mar 9;11:11. doi: 10.1186/1476-4598-11-11.

17.

Frequent heterogeneous missense mutations of GGAP2 in prostate cancer: implications for tumor biology, clonality and mutation analysis.

Cai Y, Wang J, Ren C, Ittmann M.

PLoS One. 2012;7(2):e32708. doi: 10.1371/journal.pone.0032708. Epub 2012 Feb 28.

18.

Plexin-B1 and semaphorin 4D cooperate to promote perineural invasion in a RhoA/ROK-dependent manner.

Binmadi NO, Yang YH, Zhou H, Proia P, Lin YL, De Paula AM, Guimarães AL, Poswar FO, Sundararajan D, Basile JR.

Am J Pathol. 2012 Mar;180(3):1232-42. doi: 10.1016/j.ajpath.2011.12.009. Epub 2012 Jan 15.

19.

c-MET as a potential therapeutic target and biomarker in cancer.

Sierra JR, Tsao MS.

Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35. doi: 10.1177/1758834011422557.

20.

Plexin-B2 negatively regulates macrophage motility, Rac, and Cdc42 activation.

Roney KE, O'Connor BP, Wen H, Holl EK, Guthrie EH, Davis BK, Jones SW, Jha S, Sharek L, Garcia-Mata R, Bear JE, Ting JP.

PLoS One. 2011;6(9):e24795. doi: 10.1371/journal.pone.0024795. Epub 2011 Sep 23.

Supplemental Content

Support Center